These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36257208)

  • 41. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.
    Opitz FV; Haeberle L; Daum A; Esposito I
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Olaoba OT; Yang M; Adelusi TI; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions.
    Carlomagno S; Setti C; Ortolani F; Sivori S
    Immunol Lett; 2024 Jul; 269():106898. PubMed ID: 39019404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response.
    Yang J; Zeng L; Chen R; Huang L; Wu Z; Yu M; Zhou Y; Chen R
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.
    Lekan AA; Weiner LM
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
    Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
    Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive Analysis on Prognosis and Immune Infiltration of Lysyl Oxidase Family Members in Pancreatic Adenocarcinoma With Experimental Verification.
    Jiang C; Wang M; Yao W; Lv G; Liu X; Wang G
    Front Mol Biosci; 2022; 9():778857. PubMed ID: 35433829
    [No Abstract]   [Full Text] [Related]  

  • 52. A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma.
    Katsuta E; Huyser M; Yan L; Takabe K
    Am J Cancer Res; 2021; 11(9):4294-4307. PubMed ID: 34659888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
    Osipov A; Blair AB; Liberto J; Wang J; Li K; Herbst B; Xu Y; Li S; Niu N; Rashid R; Ding D; Liu Y; Wang Z; Wolfgang CL; Burkhart RA; Laheru D; Zheng L
    Cancer Biol Med; 2021 Feb; 18(1):206-214. PubMed ID: 33628595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration.
    Zhang R; Liu Q; Peng J; Wang M; Li T; Liu J; Cui M; Zhang X; Gao X; Liao Q; Zhao Y
    J Cancer; 2020; 11(9):2371-2381. PubMed ID: 32201508
    [No Abstract]   [Full Text] [Related]  

  • 55. Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry.
    An X; Ouyang X; Zhang H; Li T; Huang YY; Li Z; Zhou D; Li QX
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30371656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
    McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
    J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy.
    Hou W; Yang B; Zhu H
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Tang R; Liu X; Wang W; Hua J; Xu J; Liang C; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Cancer Cell Int; 2021 Apr; 21(1):196. PubMed ID: 33827590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.
    Bahwal SA; Chen JJ; E L; Hao T; Chen J; Carruthers VB; Lai J; Zhou X
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2743-2757. PubMed ID: 35556163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.